VivoSeq
Other

Detrusor Overactivity

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Detrusor Overactivity is an early-stage landscape with 0 programs across 1 company. The most active players are Avera Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avera Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Recruiting2 · 25%
Unknown status1 · 13%
Terminated1 · 13%

Clinical Trials

Trial Activity

8 trials

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
Recruiting·MMackay Memorial Hospital·Phase 4·NCT06197295·200 enrolled
Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity
Recruiting·MMackay Memorial Hospital·Phase 4·NCT05968885·300 enrolled
Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
Completed·MMackay Memorial Hospital·N/A·NCT07337252·61 enrolled
Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity
Completed·UUniversità degli Studi dell'Insubria·Phase 2/3·NCT00648310
Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
Completed·—·Phase 2·NCT01682603·34 enrolled
Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility
Completed·—·Phase 2·NCT02135341·60 enrolled
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
Terminated·AAvera Pharmaceuticals·Phase 2·NCT00335660·62 enrolled
Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity
Unknown status·MMr HD Flood·Phase 4·NCT02009540·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)